Maquet Critical Care AB 2021 · Servo-n, NAVA are a trademarks of Maquet Critical Care AB · Subject to modifications · MX-8292 · English

NAVA provides both PIP and Vt in neonates that are within or lower than recommended target levels¹

Evaluating Peak Inspiratory Pressure and Tidal Volume in Premature Neonates on NAVA Ventilation – A Retrospective Study and Exploratory Analysis




The Protain Study¹ showed the clinical effectiveness of the patented Neurally Adjusted Ventilatory Assist (NAVA®) technology

and found that with the use of NAVA, nearly 80% of breaths delivered to neonates were well below the $20~\text{cmH}_2\text{O}$ (PIP), and less than the 5~ml/kg (Vt) target levels currently recommended in the neonatal literature.¹

Advantages of NAVA:

- Helps to achieve recommended PIP and Vt target levels.
- NAVA facilitates optimal synchronization between the patient and the ventilator.







Read the whole article about the Protain study and the neurally adjusted ventilation mode NAVA.

Getinge is a registered trademark of Getinge AB, its subsidiaries, or affiliates in the United States or other countries. NAVA is a trademark of Maquet Critical Care AB. Copyright 2021 Getinge AB or its subsidiaries or affiliates. All rights reserved.

 $The products \, may \, not \, be \, approved \, for \, distribution \, in \, your \, country, \, please \, check \, with \, your \, local \, Getinge \, sales \, team.$

This document is intended to provide information to an international audience outside of the US.

